| 生物活性 |
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM), synthesized by conjugating 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (MS-U66285) with an anti-c-Kit human monoclonal antibody NN2101 (MS-Y91737); it rapidly internalizes and inhibits SCF-driven signaling, induces cell cycle arrest and apoptosis (apoptosis) through payload delivery, exhibits no Fc-mediated ADCC or CDC effector functions due to reduced FcγR binding, demonstrates significant c-Kit-dependent antitumor efficacy in multiple tumor models, and can be used for research related to small cell lung cancer (SCLC), gastrointestinal stromal tumor (GIST), and acute myeloid leukemia (AML). |
体外研究 (In Vitro) |
NN3201 (1 µg/mL,1 小时) 与 c-Kit 高/中表达细胞系表现出剂量依赖性结合,在 315 pM 时达到饱和,未观察到其与 c-Kit 低表达或阴性细胞系结合。
NN3201 (1 µg/mL,0.5-24 小时) 在 c-Kit 阳性的 GIST-T1 细胞中快速 (30 分钟内) 并持续内化,信号在 24 小时内持续增强,且其内化作用依赖于 c-Kit。
NN3201 (3-7 天) 在一组 c-Kit 阳性细胞系中表现出由其 MMAE 有效载荷介导的强效且 c-Kit 依赖性细胞毒性,GI50 值分别为 0.09 nM (GIST-T1)、0.69 nM (GIST-430)、0.12 nM (GIST-430/654) 和 17.06 nM (NCI-H1048)。
NN3201 (0.01-1 µg/mL,1 小时) 剂量依赖性地降低 NCI-H1048 细胞中 SCF 介导的 c-Kit (Y719、Y568/570)、Erk1/2 和 Akt (S473) 的磷酸化,而在 GIST-430/654 细胞中仅部分抑制了 pY568/570 c-Kit 和 pErk1/2 的磷酸化。
NN3201 (1 µg/mL,1-3 天) 通过持续内化诱导 c-Kit 降解和信号抑制,从而引发细胞凋亡,其表现为 caspase-3 和 caspase-7 的裂解增加。
NN3201 (5 µg/mL,24-48 小时) 诱导细胞周期阻滞于 G2/M 期和亚 G1 期,这归因于其释放的 MMAE 有效载荷的微管 (Microtubule/Tubulin) 的破坏作用。
NN3201 (4 µg/mL,7 天) 引发了强烈的旁观者效应,该效应由 NN3201 处理的 GIST-430/654 细胞释放的游离 MMAE 介导,从而导致邻近的 c-Kit 表达水平极低的 MCF7-GFP⁺ 癌细胞死亡。
Cell Viability Assay
| Cell Line: |
MCF7-GFP+ cells |
| Concentration: |
4 μg/mL |
| Incubation Time: |
7 days |
| Result: |
Exhibited negligible cytotoxicity (GI50 >20 µg/mL) against the c-Kit-negative MCF7-GFP⁺ cell line, consistent with its target-dependent mechanism and in sharp contrast to the potent activity of its free payload, MMAE (GI50 = 4.96 nM). |
Cell Cycle Analysis
| Cell Line: |
GIST-430/654 and NCI-H1048 cells |
| Concentration: |
1 μg/mL |
| Incubation Time: |
24 and 48 h |
| Result: |
Induced substantial cell cycle arrest at the G2/M phase and increased the sub-G1 population in both cell lines. |
Western Blot Analysis
| Cell Line: |
GIST-430/654 and MCI-H1048 cells |
| Concentration: |
1 μg/mL |
| Incubation Time: |
1, 2, and 3 days |
| Result: |
Induced a time-dependent degradation of c-Kit in both cell lines.
Increased levels of cleaved caspase-3 and caspase-7.
Eventually inhibited the c-Kit downstream signaling pathway by sustained internalization and degradation of the NN3201-c-Kit complex over 3 days.
|
|
体内研究 (In Vivo) |
NN3201 (0.5-10 mg/kg,静脉注射,每 10 天给药一次,共 3 次;或每周给药一次,共 3 次) 在多种胃肠道间质瘤 (GIST) 和小细胞肺癌 (SCLC) 肿瘤小鼠模型中,表现出显著的 c-Kit 依赖性抗肿瘤功效。
| Animal Model: |
Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with GIST-T1 cells |
| Dosage: |
0.5, 1.5 and 3.0 mg/kg |
| Administration: |
i.v., Q10D x 3 |
| Result: |
Completely regressed tumor volume for up to 112 days at 1.5 and 3 mg/kg, with Imatinib (MS-J72535) (100 mg/kg, p.o., Q1D x 30) only inhibited tumor progression during the treatment period.
Induced no body weight loss but rather an increase as tumor size enlarges. |
| Animal Model: |
NOG mice (5-6 weeks old) subcutaneously injected with GIST-430/654 cells |
| Dosage: |
1, 3 and 5 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Induced significant tumor shrinkage at 3 mg/kg and 5 mg/kg, and stably controlled until day 42 and 49, respectively.
Induced tumor growth inhibition (TGI) of 47.2% on day 21 at 1 mg/kg, which was similar to that by 30 mg/kg of Sunitinib (MS-E55855) (30 mg/kg, p.o., Q1D x 21; TGI of 45.2% on day 21).
Induced no body weight loss but rather an increase as tumor size enlarges. |
| Animal Model: |
Female NOD/SCID mice subcutaneously implanted with GS5108 tumors |
| Dosage: |
3, 5 and 10 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Induced durable tumor stasis at 10 mg/kg, which was followed by significant tumor regression for up to 60 days.
Demonstrated superior in vivo efficacy over all standard-of-care (SoC) treatments in the 3rd line GIST models.
Induced no body weight loss but rather an increase as tumor size enlarges. |
| Animal Model: |
Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H526 cells |
| Dosage: |
1, 1.5, 2, 2.5 and 3 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Induced complete regression of the tumor with no regrowth after 70 and 84 days at 2.5 and 3 mg/kg.
Exhibited 84.9% of TGI compared to the vehicle control on day 17 at 2 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
|
| Animal Model: |
Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells |
| Dosage: |
1, 3, and 5 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Showed TGI of 95.1 % on day 21 at 1 mg/kg, better than the combination of Carboplatin (MS-L77931) (60 mg/kg, i.p., day 0 and 10) and Etoposide (MS-Z04043) (3 mg/kg. i.p., day 0~4 and 10~14; TGI = 70.51% on day 21).
Induced complete tumor remission for up to 35 days and 56 days at 3 mg/kg and 5 mg/kg, respectively.
Induced no body weight loss but rather an increase as tumor size enlarges. |
| Animal Model: |
Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells |
| Dosage: |
5 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Was able to reduce the tumor volume to below baseline, whereas neither Topotecan (MS-X01138) (0.83 mg/kg, i.p., BIW x 3) nor Irinotecan (MS-O02109) (33 mg/kg, i.v., Q1W x 3) could achieve this.
Induced no body weight loss but rather an increase as tumor size enlarges. |
| Animal Model: |
Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with SHP-77 cells |
| Dosage: |
1, 3, and 5 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Exhibited no in vivo potency in SHP-77 xenografts, where c-Kit expression is negligible, confirming its c-Kit driven property.
Induced no body weight loss but rather an increase as tumor size enlarges. |
| Animal Model: |
Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-1252 tumors |
| Dosage: |
1, 3, and 5 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Dose-dependently inhibited tumor growth.
Achieved 70 days of complete regression at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
|
| Animal Model: |
Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-2093 tumors |
| Dosage: |
1, 3, and 5 mg/kg |
| Administration: |
i.v., Q1W x 3 |
| Result: |
Induced tumor stasis until day 27 with TGI of 84.8% at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
|
|